Growing evidence suggests that overexpression of TrkC, a member of the Trk family of neurotrophin receptors, could drive tumorigenesis, invasion and metastatic capability in cancer cells. However, relatively little is known about the mechanism of TrkC-mediated oncogenesis. The TrkC gene is a partner of the Tel-TrkC (ETV6-NTRK3) chimeric tyrosine kinase, a potent oncoprotein expressed in tumors derived from multiple cell lineages. Recently, we have shown that ETV6-NTRK3 suppresses transforming growth factor-b (TGF-b) signaling by directly binding to the type II TGF-b receptor (TbRII). Here, we report that expression of TrkC also suppresses TGF-b-induced Smad2/3 phosphorylation and transcriptional activation. Silencing TrkC expression by small interfering RNA in the highly metastatic 4T1 mammary tumor cell line expressing endogenous TrkC significantly enhanced TGFb-induced Smad2/3 phosphorylation and restored TGF-b growth inhibitory activity. In contrast, expression of TrkC in 67NR cells, in which TrkC is not expressed, suppressed TGF-b transcriptional activation. Moreover, we show that TrkC directly binds to the TbRII, thereby preventing it from interacting with the type I TGF-b receptor (TbRI). These results indicate that TrkC is an inhibitor of TGF-b tumor suppressor activity.
Introduction
TrkC is a member of the Trk family of neurotrophin receptors that regulate proliferation, survival, commitment and differentiation of neurons in response to neurotrophins (Chao and Bothwell, 2002) . Neurotrophins and their corresponding receptors have been shown to induce a variety of pleiotropic responses in malignant cells, including enhanced tumor invasiveness and chemotaxis (Nakagawara, 2001) . TrkC is highly expressed in favorable neuroblastomas and medulloblastomas (Segal et al., 1994; Yamashiro et al., 1997; Grotzer et al., 2000) . Malignant keratinocytes express TrkA, B and C as a unique survival pathway, and higher levels of expression of TrkA, B and C may predict perineural invasion in cutaneous squamous cell carcinoma. A recent study shows that TrkB is a potent and specific suppressor of caspase-associated anoikis of non-malignant epithelial cells (Douma et al., 2004) .
The trkC gene is also known to be a partner of the ETV6-NTRK3 (Tel-TrkC) fusion gene, which results from a reciprocal chromosomal translocation, t(12;15)-(p13;q25), in congenital fibrosarcoma, a cellular variant of congenital mesoblastic nephroma, acute myeloid leukemia and human secretory breast carcinoma (Knezevich et al., 1998; Eguchi et al., 1999; Tognon et al., 2002) . Recently, we found that ETV6-NTRK3 chimeric tyrosine kinase (EN) suppresses TGF-b signaling by directly binding to the type II TGF-b receptor (TbRII), thereby preventing it from interacting with the type I TGF-b receptor (TbRI) (Jin et al., 2005) . This finding suggests that TrkC oncogenic tyrosine kinase can block TGF-b tumor suppressor activity.
Besides activation of TrkC by fusion with multimerizing proteins, TrkC activation in human tumors seems to occur through overexpression of the full-length protein. A variety of non-neuronal tissues have also been shown to express TrkC (Grotzer et al., 2000; Satoh et al., 2001; Hisaoka et al., 2002) ; however, relatively little is known about whether TrkC activity is also essential to maintain the malignant properties in human tumors. Interestingly, recent sequence analysis of the tyrosine kinome in colorectal cancers has revealed fivepoint mutations in the trkC gene, both within its kinaseencoding domain (Bardelli et al., 2003) . In this study, we attempted to examine whether overexpression of TrkC suppresses the TGF-b tumor suppressor pathway.
Results

Overexpression of TrkC suppresses TGF-b signaling
Our previous study showed that ETV6-NTRK3 (TelTrkC) EN suppresses TGF-b signaling (Jin et al., 2005) . To examine whether TrkC expression also influences TGF-b signaling, we generated NIH3T3 cells expressing TrkC by infection of recombinant retroviruses carrying trkC cDNA or an empty MSCVpac vector as a control (Figure 1a ). TrkC expression significantly suppressed TGF-b1-stimulated endogenous Smad2/3 phosphorylation in NIH3T3 cells (Figure 1b) . To test whether TrkC influences TGF-b1-induced transcriptional activation, we transfected control or TrkC-overexpressing cells with the TGF-b-responsive 3TP-lux reporter construct (Wrana et al., 1992) or the Smad-binding element (SBE4)-luc reporter construct (Zawel et al., 1998) , which contains four SBE sites in tandem. Expression of TrkC dramatically repressed the TGF-b1-dependent activities of these reporter gene constructs (Figures 2a and b) . We also assessed the effects of TrkC expression on SBE4-luc or 3TP-lux activity by co-transfection of the TrkC expression plasmid and the SBE4-luc or the 3TP-Lux reporter as well as the TbRII expression construct in NIH3T3 cells, and observed TrkC-specific suppression of TGF-b1-induced transcriptional activity in NIH3T3 cells (Figures 2c and d) .
One of the critical cellular activities of TGF-b is the transcriptional activation of several matrix-related genes, including those encoding collagen and the plasminogen activation inhibitor-1 (PAI-1). Activation of PAI-1 mRNA expression was markedly enhanced by TGF-b1 in control NIH3T3 cells. However, induction of PAI-1 transcripts by TGF-b1 was markedly suppressed in TrkC-expressing NIH3T3 cells. (Figure 2e ). The TGF-b1-induced PAI-1 promoter activity was also markedly suppressed in TrkC-expressing NIH3T3 cells (Figure 2f ).
We also examined the effect of K252a (Horton et al., 2001) , an inhibitor of the Trk tyrosine kinases, to assess further whether TrkC kinase activity is required for its ability to suppress TGF-b1-mediated Smad2/3 phosphorylation. TGF-b1-induced Smad2/3 phosphorylation was markedly reduced in NIH3T3 cells expressing TrkC, whereas pretreatment of K252a restored the degree of Smad2/3 phosphorylation dose-dependently ( Figure 3 ). This indicates that TrkC kinase activity is required for suppression of TGF-b signaling.
Effect of TrkC overexpression or TrkC silencing on TGF-b signaling
We have investigated recently TrkC expression in a mouse mammary model that consists of three distinct tumor cell lines, 67NR, 4TO7 and 4T1. All three cell lines are derived from a single mammary tumor that arose spontaneously in a wild-type BALB/c mouse. 67NR cells form primary tumors, but no tumor cells are detectable in any distant tissue. Cells of the 4TO7 line are able to spread to lung, but cannot establish visible metastatic nodules. Cells of the 4T1 line are able to complete all steps of metastasis and form visible metastatic nodules in lung efficiently. The trkC mRNA was highly expressed in highly metastatic 4T1 tumor cells, but not expressed in 67NR cells (data not shown). Neurotrophin-3, a ligand for TrkC, was expressed in both 67NR and 4T1 cells (Supplementary Figure 1) .
We examined TGF-b1 sensitivity in these cell lines to see whether TrkC expression has any effect on TGF-b1 signaling. TGF-b1 markedly stimulated endogenous Smad2/3 phosphorylation in 67NR cells. However, in comparison with 67NR cells, the level of TGF-b1-stimulated Smad2/3 phosphorylation was significantly lower in 4T1 cells, even though levels of total Smad2 and 3 proteins are higher in 4T1 cells (Figure 4a ). To explore further in detail the role of TrkC in TGF-b signaling, we used 67NR cells infected with recombinant retroviruses carrying a TrkC cDNA or empty MSCVpac vector as a control. We then examined Smad2 phosphorylation and TGF-b1-induced transcriptional activation in 67NR cells expressing TrkC. The level of phosphorylated Smad2 was markedly attenuated and the TGFb1-dependent activity of the SBE4-luc reporter was significantly repressed in TrkC-expressing cells (Figures  4b and c) .
To investigate further the role of TrkC in TGF-b signaling, we used siRNA technology to knockdown TrkC in the highly metastatic 4T1 cells. Expression of two different siRNAs strongly reduced the endogenous TrkC levels in 4T1 cells as compared to control cells (Figures 5c and d) . Therefore, our data strongly suggest that TrkC directly interacts with TbRII under physiological conditions. We next examined whether activation of TrkC kinase is required for the interaction between TrkC and TbRII. The kinase dead TrkC-K572N mutant, which fails to autophosphorylate, did not interact with TbRII (Figure 5e ). We also examined the effect of K252a on the formation of protein complexes between TrkC and TbRII to see whether activation of TrkC kinase is required for the interaction. Treatment of cells with K252a suppressed the formation of protein complexes between TrkC and TbRII (Figure 5f ). Suppression of TGF-b signaling by TrkC W Jin et al the types II and I receptor serine-threonine kinases at the plasma membrane (Wrana et al., 1992) . Within this receptor complex, the TbRII kinase phosphorylates the TbRI within a serine/threonine-rich domain located immediately amino terminal to the kinase domain of the TbRI (the GS box) (Wieser et al., 1995) . This results in activation of TbRI with subsequent initiation of downstream signaling pathways. Since TrkC interacts with TbRII, but not with TbRI, we hypothesized that TrkC may exert its effect by blocking the ability of TbRII to recruit and activate TbRI. To test whether TrkC/TbRII complex formation inhibits the ability of TbRII to phosphorylate TbRI, we immunoprecipitated endogenous TbRI in NIH3T3 cells stably expressing TrkC after 30 min of stimulation with TGF-b1. The immunoprecipitated TbRI was immunoblotted with anti-phosphoserine. Serine phosphorylation of TbRI was enhanced by TGF-b1 in control cells, whereas enhancement of serine phosphorylation by TGF-b1 was blocked in stably expressing TrkC cells (Figure 6a ).
To examine whether TrkC suppresses the ability of TbRII kinase to activate TbRI by blocking TbRI-TbRII complex formation, Flag-TbRII was co-expressed with V5-TrkC along with HA-TbRI in 293T cells. As expected, TbRII-associated TbRI was only observed after stimulation with TGF-b1 (compare lanes 2 and 3, Figure 6b ). Co-expression of TrkC significantly reduced the level of TbRI associated with TbRII (compare lanes 4 and 5, Figure 6b ). TGF-b1 treatment also induced serine phosphorylation of TbRI, but this was markedly attenuated by co-expression of TrkC (Figure 6b ). These findings strongly indicate that TrkC inhibits TGF-b signaling through its interaction with TbRII, and that this association inhibits TbRI-TbRII complex formation (Figure 6c ).
Discussion
The Trk family of neurotrophin receptors is emerging as an important player in carcinogenic progression. Trk appear to have a high capacity for ligand-independent activation, presumably via spontaneous interactions. The prevalence of overexpression of the Trk family of neurotrophin receptors in human cancers has also prompted interest in these receptors as potential therapeutic targets (Ruggeri et al., 1999) . In the present study, we have demonstrated that TrkC suppresses TGF-b signaling. TrkC specifically interacts with TbRII and blocks its ability to activate downstream signaling, providing evidence for direct crosstalk between two distinct kinase-signaling cascades.
TrkC is frequently overexpressed in human cancers including pancreatic and prostate carcinoma, medulloblastoma, pediatric brain tumor, neuroblastoma, leiomyosarcoma, and basal cell and cutaneous squamous cell carcinomas (Segal et al., 1994; Ryden et al., 1996; Brodeur et . This corresponds to the acquisition of potent tumorigenic, invasive and metastatic capacities, indicating that TrkC may contribute directly to human malignancies. In this study, we show that TrkC also renders cells resistant to TGF-b tumor suppressor activity, suggesting that suppression of the TGF-b tumor suppressor pathway may contribute to TrkC-mediated tumorigenicity. TGF-b, the prototypic multifunctional cytokine, participates in the regulation of vital cellular activities such as proliferation and differentiation (Roberts and Sporn, 1993; Massagu, 1998) . Another essential function of TGF-b is its tumor suppressor activity in a variety of different human cell types. Human cancer cells frequently demonstrate resistance to the normal growth-inhibitory effects of TGF-b, and it has been proposed that the development of such TGF-b resistance represents a significant step during carcinogenesis (Park et al., 1994; Markowitz and Roberts, 1996; Kim et al., 2000) . Because the effects of TGF-b are dependent on the expression of specific cell-surface receptors, it has been proposed that the regulation of the expression of these receptors will emerge as an important mechanism for determining cellular responsiveness to TGF-b. Many human cancer cell lines, including breast cancer cell lines, have TGF-b resistance without detectable alterations in the TbRII gene (Hahm et al., 1999; Lee et al., 2001) . These cells express low or undetectable levels of TbRI and TbRII genes, suggesting that abnormalities of transcriptional regulation might be involved. The cause and effect relationship between the loss of TbRII expression and the resistance to TGF-b has been firmly established by published studies that reported that transfecting breast, colon, liver and gastric cells with wild-type TbRII successfully restored TGF-b growthinhibitory activity (Sun et al., 1994; Chang et al., 1997) .
In the present study, we have demonstrated another unique mechanism to suppress TGF-b tumor suppressor activity, namely inactivation of the TbRII receptor kinase activity by TrkC receptor tyrosine kinase. TrkC interaction with TbRII suppresses downstream TGF-b signaling by blocking the TbRI recruitment to TbRII. This observation was confirmed in the highly metastatic 4T1 mammary cancer cell line which expresses TrkC. The level of phosphorylated Smad2 in response to TGFb1 was markedly enhanced and TGF-b1 growth inhibitory activity was restored when endogenous TrkC was silenced in 4T1 cells. These observations suggest that the inactivation of TbRII receptor kinase activity may be important in modulating responsiveness to TGF-b during carcinogenesis.
Materials and methods
Cell culture antibodies and reagent Breast cancer cell lines (67NR, 4T1 and Hs578T) were maintained in Dulbecco's modified Eagle's medium high glucose (Gibco, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum, and the MCF7 cell line was maintained in RPMI1640 medium (Gibco) supplemented with 10% heat-inactivated fetal bovine serum at 371C in a humidified 5% CO 2 incubator. Antibodies were obtained from the following companies: anti-TrkC (C-14, 798), anti-HA (Y-11) and anti-TbRII from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-phospho-Smad2 and -Smad3 from Cell Signaling Technology (Danvers, MA, USA); anti-b-actin and anti-Flag from Sigma-Aldrich (St Louis, MO, USA). Pharmacological inhibition was performed with the protein kinase inhibitor, K252a, from Calbiochem (San Diego, CA, USA).
Plasmids
Each of two siRNA-coding oligos against mouse and human TrkC were designed and verified to be specific to TrkC using Blast search against the mouse and human genome, respectively. To construct hairpin-type single RNAi vectors, 5 ml (100 mM) of the synthesized sense and antisense oligonucleotides (Supplementary Table 1) were combined with 1 ml of 1 M NaCl and annealed by incubation at 951C for 2 min, followed by rapid cooling to 721C, and ramp cooling to 41C over a period of 2 h. The mouse and human TrkC-siRNA insert were subcloned into the XbaI/XhoI sites of the pFG12 lenti-virus vector. A control siRNA, which does not match any known mouse coding cDNA, was used as a control.
Immunoblotting and immunoprecipitation 293T cells were used for the detection of protein-protein interaction in vivo. 293T cells were transiently transfected with the indicated plasmids. After a 24-h transfection, cells were switched to 0.2% serum overnight. Cells were lysed in a buffer containing 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.5), 150 mM NaCl, 1% Triton X-100, 10% glycerol, 5 mM ethylenediaminetetraacetic acid and protease inhibitor mixture (Roche, Gipf-Oberfrick, Switzerland). Extracts were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by electrotransfer to poly(vinylidene difluoride) membranes and probed with polyclonal or monoclonal antisera, followed by horseradish peroxidase-conjugated anti-rabbit, anti-mouse immunoglobulin, respectively, and visualized by chemiluminescence according to the manufacturer's instructions (Pierce, Rockford, IL, USA). For immunoprecipitation, the cell lysates were incubated with the appropriate antibody for 1 h, followed by incubation with g-bind beads (Amersham Pharmacia Biosciences (Piscataway, NJ, USA) for 1 h at 41C. Beads were washed four times with the buffer used for cell solubilization. Immune complexes were then eluted by boiling for 3 min in 2 Â Laemmli buffer (pH 6.8), and then extracts were analysed by immunoblotting as described above.
Transfection and reporter assays NIH3T3 cells expressing TrkC or 293T cells were transiently transfected with 3TP-Lux, SBE4-luc and the internal control pCMV-b-gal in six-well plates using Lipofectin (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. After a 24-h transfection, cells were treated with 5 ng/ml TGF-b1 for 24 h in medium. Luciferase activity was quantified using the Enhanced Luciferase Assay Kit (BD Biosciences, Franklin Lake, NJ, USA). Values were normalized with the b-gal activity. All assays were performed in triplicate and represented as the mean (7s.e.) of three independent transfections.
